BeOne culls five cancer programs and an autoimmune Phase 2
BeOne Medicines has greatly expanded its pipeline over the years, bringing 18 new molecular entities to the fore across 2024 and 2025. But that also means the drugmaker will likely cull more experimental medicines as ...
ORIGINAL SOURCE →via Endpoint News
ADVERTISEMENT
⚡ STAY AHEAD
Events like this, convergence-verified across 689 sources, land in your inbox every Sunday. Free.
GET THE SUNDAY BRIEFING →RELATED · energy
- [ENERGY] Iran’s aging tankers used for oil reserves as blockade strains storage capacity
- [ENERGY] US Navy strikes Iranian-flagged ship trying to break Strait of Hormuz blockade from Gulf of Oman
- [ENERGY] TREASURIES-US bond yields decline as oil tumbles on possible Iran agreement - marketscreener.com
- [ENERGY] Oil slides to two-week lows on hopes of U.S.-Iran deal
- [ENERGY] Nuclear Security News and Member Updates Roundup, April 2026
- [ENERGY] Morgan Stanley Just Cut Its U.S. Growth Forecast Because Gas Prices Are “More Than Enough” to Wipe Out Bigger Tax Refunds - AOL.com